secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001493152-23-010456
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity reports FY2022 net loss $8.2M ($1.81/sh), revenue $5K; cash $11.4M, plans pivotal trial 2023
--------------------------------------------------------------------------------

- FY2022 net loss $8.2M ($1.81/sh) vs $6.3M ($2.36/sh) in 2021; revenue $5K from CyPath Lung LDT.
- Q4 2022 net loss $1.7M, revenue $2,500; cash and equivalents $11.4M as of Dec 31, 2022.
- Raised net $6.0M from IPO in Sep 2022; additional $7.8M from warrant/option exercises.
- CyPath Lung clinical validation: 92% sensitivity, 87% specificity in high-risk patients; AUC 94%.
- Pivotal trial for FDA clearance to recruit 1,800 patients starting in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/0001493152-23-010456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer